Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 23, 2026Cancer Biology and MedicineOpen Access

Apatinib enhances targeted immunotherapy via the IL-6-gp130-PI3K pathway in HER2-positive gastric cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RTRuoxi TianZSZiyue ShaSZShasha Zhang

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates apatinib-based immunotherapy's effectiveness in HER2-positive gastric cancer, suggesting a new treatment option.

Key Points

  • This study evaluates the efficacy of apatinib-based immunotherapy in HER2-positive gastric cancer patients who cannot tolerate chemotherapy.
  • Utilized KEGG/GO pathway analyses to explore pathways impacted by apatinib and trastuzumab sensitivity.
  • Conducted experiments in HER2-positive gastric cancer cell lines, tumor cell line-derived xenografts, and a small patient group.
  • Applied co-immunoprecipitation, western blotting, immunohistochemistry, and immunofluorescence for mechanistic studies.
  • Apatinib significantly enhanced trastuzumab's inhibition of HER2-positive gastric cancer via the IL-6/gp130/PI3K pathway.
  • The combination of apatinib with tocilizumab showed synergistic effects in inhibiting HER2-positive gastric cancer in hHSC-CDXs and patients.
  • Apatinib treatment was associated with decreased angiogenesis, reduced M2-like tumor-associated macrophages, and increased CD8+ T cell infiltration.

Cite This Study

Tian et al. (2026) studied this question.

synapsesocial.com/papers/6a61b02ffaa9903c5116ad6ehttps://doi.org/10.20892/j.issn.2095-3941.2025.0687
View Full Paper
Ask AI
Bookmark
Share